Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

Mitochondrial NIX Promotes Tumor Survival in the Hypoxic Niche of Glioblastoma.

Jung J, Zhang Y, Celiku O, Zhang W, Song H, Williams BJ, Giles AJ, Rich JN, Abounader R, Gilbert MR, Park DM.

Cancer Res. 2019 Oct 15;79(20):5218-5232. doi: 10.1158/0008-5472.CAN-19-0198. Epub 2019 Sep 5.

PMID:
31488423
2.

MicroRNA-29a inhibits glioblastoma stem cells and tumor growth by regulating the PDGF pathway.

Yang Y, Dodbele S, Park T, Glass R, Bhat K, Sulman EP, Zhang Y, Abounader R.

J Neurooncol. 2019 Oct;145(1):23-34. doi: 10.1007/s11060-019-03275-z. Epub 2019 Sep 3.

PMID:
31482267
3.

Ethanol Extract of Securidaca longipedunculata Induces Apoptosis in Brain Tumor (U87) Cells.

Ngulde SI, Sandabe UK, Abounader R, Dawson TK, Zhang Y, Iliya I, Hussaini IM.

Biomed Res Int. 2019 Feb 26;2019:9826590. doi: 10.1155/2019/9826590. eCollection 2019.

4.

Myt1 and Myt1l transcription factors limit proliferation in GBM cells by repressing YAP1 expression.

Melhuish TA, Kowalczyk I, Manukyan A, Zhang Y, Shah A, Abounader R, Wotton D.

Biochim Biophys Acta Gene Regul Mech. 2018 Nov;1861(11):983-995. doi: 10.1016/j.bbagrm.2018.10.005. Epub 2018 Oct 10.

PMID:
30312684
5.

Discovery and Therapeutic Exploitation of Mechanisms of Resistance to MET Inhibitors in Glioblastoma.

Cruickshanks N, Zhang Y, Hine S, Gibert M, Yuan F, Oxford M, Grello C, Pahuski M, Dube C, Guessous F, Wang B, Deveau C, Saoud K, Gallagher I, Wulfkuhle J, Schiff D, Phan S, Petricoin E, Abounader R.

Clin Cancer Res. 2019 Jan 15;25(2):663-673. doi: 10.1158/1078-0432.CCR-18-0926. Epub 2018 Sep 10.

PMID:
30201763
6.

The p53 Pathway in Glioblastoma.

Zhang Y, Dube C, Gibert M Jr, Cruickshanks N, Wang B, Coughlan M, Yang Y, Setiady I, Deveau C, Saoud K, Grello C, Oxford M, Yuan F, Abounader R.

Cancers (Basel). 2018 Sep 1;10(9). pii: E297. doi: 10.3390/cancers10090297. Review.

7.

Correction to: Multiple receptor tyrosine kinases converge on microRNA-134 to control KRAS, STAT5B, and glioblastoma.

Zhang Y, Kim J, Mueller AC, Dey B, Yang Y, Lee DH, Hachmann J, Finderle S, Park DM, Christensen J, Schiff D, Purow B, Dutta A, Abounader R.

Cell Death Differ. 2019 Jan;26(1):197. doi: 10.1038/s41418-018-0145-0.

8.

Combined c-Met/Trk Inhibition Overcomes Resistance to CDK4/6 Inhibitors in Glioblastoma.

Olmez I, Zhang Y, Manigat L, Benamar M, Brenneman B, Nakano I, Godlewski J, Bronisz A, Lee J, Abbas T, Abounader R, Purow B.

Cancer Res. 2018 Aug 1;78(15):4360-4369. doi: 10.1158/0008-5472.CAN-17-3124. Epub 2018 May 29.

9.

A new practical and versatile mouse model of proneural glioblastoma.

Abounader R.

Neuro Oncol. 2018 Feb 19;20(3):299-301. doi: 10.1093/neuonc/nox233. No abstract available.

10.

p53 and NF 1 loss plays distinct but complementary roles in glioma initiation and progression.

Gonzalez PP, Kim J, Galvao RP, Cruickshanks N, Abounader R, Zong H.

Glia. 2018 May;66(5):999-1015. doi: 10.1002/glia.23297. Epub 2018 Feb 2.

PMID:
29392777
11.

Noncoding RNAs in Glioblastoma.

Zhang Y, Cruickshanks N, Pahuski M, Yuan F, Dutta A, Schiff D, Purow B, Abounader R.

In: De Vleeschouwer S, editor. Glioblastoma [Internet]. Brisbane (AU): Codon Publications; 2017 Sep 27. Chapter 6.

12.

Targeting the mesenchymal subtype in glioblastoma and other cancers via inhibition of diacylglycerol kinase alpha.

Olmez I, Love S, Xiao A, Manigat L, Randolph P, McKenna BD, Neal BP, Boroda S, Li M, Brenneman B, Abounader R, Floyd D, Lee J, Nakano I, Godlewski J, Bronisz A, Sulman EP, Mayo M, Gioeli D, Weber M, Harris TE, Purow B.

Neuro Oncol. 2018 Jan 22;20(2):192-202. doi: 10.1093/neuonc/nox119.

13.

Combined CDK4/6 and mTOR Inhibition Is Synergistic against Glioblastoma via Multiple Mechanisms.

Olmez I, Brenneman B, Xiao A, Serbulea V, Benamar M, Zhang Y, Manigat L, Abbas T, Lee J, Nakano I, Godlewski J, Bronisz A, Abounader R, Leitinger N, Purow B.

Clin Cancer Res. 2017 Nov 15;23(22):6958-6968. doi: 10.1158/1078-0432.CCR-17-0803. Epub 2017 Aug 16.

14.

Role and Therapeutic Targeting of the HGF/MET Pathway in Glioblastoma.

Cruickshanks N, Zhang Y, Yuan F, Pahuski M, Gibert M, Abounader R.

Cancers (Basel). 2017 Jul 11;9(7). pii: E87. doi: 10.3390/cancers9070087. Review.

15.

Targetable T-type Calcium Channels Drive Glioblastoma.

Zhang Y, Cruickshanks N, Yuan F, Wang B, Pahuski M, Wulfkuhle J, Gallagher I, Koeppel AF, Hatef S, Papanicolas C, Lee J, Bar EE, Schiff D, Turner SD, Petricoin EF, Gray LS, Abounader R.

Cancer Res. 2017 Jul 1;77(13):3479-3490. doi: 10.1158/0008-5472.CAN-16-2347. Epub 2017 May 16.

16.

Expression of lncRNAs in Low-Grade Gliomas and Glioblastoma Multiforme: An In Silico Analysis.

Reon BJ, Anaya J, Zhang Y, Mandell J, Purow B, Abounader R, Dutta A.

PLoS Med. 2016 Dec 6;13(12):e1002192. doi: 10.1371/journal.pmed.1002192. eCollection 2016 Dec.

17.

Combined PDGFR and HDAC Inhibition Overcomes PTEN Disruption in Chordoma.

Lee DH, Zhang Y, Kassam AB, Park MJ, Gardner P, Prevedello D, Henry S, Horbinski C, Beumer JH, Tawbi H, Williams BJ, Shaffrey ME, Egorin MJ, Abounader R, Park DM.

PLoS One. 2015 Aug 6;10(8):e0134426. doi: 10.1371/journal.pone.0134426. eCollection 2015.

18.

Targeting MET for glioma therapy.

Awad AJ, Burns TC, Zhang Y, Abounader R.

Neurosurg Focus. 2014 Dec;37(6):E10. doi: 10.3171/2014.9.FOCUS14520. Review.

PMID:
25434379
19.

Novel anti-apoptotic microRNAs 582-5p and 363 promote human glioblastoma stem cell survival via direct inhibition of caspase 3, caspase 9, and Bim.

Floyd DH, Zhang Y, Dey BK, Kefas B, Breit H, Marks K, Dutta A, Herold-Mende C, Synowitz M, Glass R, Abounader R, Purow BW.

PLoS One. 2014 May 7;9(5):e96239. doi: 10.1371/journal.pone.0096239. eCollection 2014.

20.

A new lncRNA, APTR, associates with and represses the CDKN1A/p21 promoter by recruiting polycomb proteins.

Negishi M, Wongpalee SP, Sarkar S, Park J, Lee KY, Shibata Y, Reon BJ, Abounader R, Suzuki Y, Sugano S, Dutta A.

PLoS One. 2014 Apr 18;9(4):e95216. doi: 10.1371/journal.pone.0095216. eCollection 2014.

21.

MicroRNA-608 and microRNA-34a regulate chordoma malignancy by targeting EGFR, Bcl-xL and MET.

Zhang Y, Schiff D, Park D, Abounader R.

PLoS One. 2014 Mar 12;9(3):e91546. doi: 10.1371/journal.pone.0091546. eCollection 2014.

22.

Regulatory factor X1 is a new tumor suppressive transcription factor that acts via direct downregulation of CD44 in glioblastoma.

Feng C, Zhang Y, Yin J, Li J, Abounader R, Zuo Z.

Neuro Oncol. 2014 Aug;16(8):1078-85. doi: 10.1093/neuonc/nou010. Epub 2014 Feb 12.

23.

Multiple receptor tyrosine kinases converge on microRNA-134 to control KRAS, STAT5B, and glioblastoma.

Zhang Y, Kim J, Mueller AC, Dey B, Yang Y, Lee DH, Hachmann J, Finderle S, Park DM, Christensen J, Schiff D, Purow B, Dutta A, Abounader R.

Cell Death Differ. 2014 May;21(5):720-34. doi: 10.1038/cdd.2013.196. Epub 2014 Jan 17. Erratum in: Cell Death Differ. 2019 Jan;26(1):197.

24.

microRNA-148a is a prognostic oncomiR that targets MIG6 and BIM to regulate EGFR and apoptosis in glioblastoma.

Kim J, Zhang Y, Skalski M, Hayes J, Kefas B, Schiff D, Purow B, Parsons S, Lawler S, Abounader R.

Cancer Res. 2014 Mar 1;74(5):1541-53. doi: 10.1158/0008-5472.CAN-13-1449. Epub 2014 Jan 14.

25.

A miR-297/hypoxia/DGK-α axis regulating glioblastoma survival.

Kefas B, Floyd DH, Comeau L, Frisbee A, Dominguez C, Dipierro CG, Guessous F, Abounader R, Purow B.

Neuro Oncol. 2013 Dec;15(12):1652-63. doi: 10.1093/neuonc/not118. Epub 2013 Oct 24.

26.

microRNA-34a promotes DNA damage and mitotic catastrophe.

Kofman AV, Kim J, Park SY, Dupart E, Letson C, Bao Y, Ding K, Chen Q, Schiff D, Larner J, Abounader R.

Cell Cycle. 2013 Nov 15;12(22):3500-11. doi: 10.4161/cc.26459. Epub 2013 Sep 19.

27.

A novel PTEN/mutant p53/c-Myc/Bcl-XL axis mediates context-dependent oncogenic effects of PTEN with implications for cancer prognosis and therapy.

Huang X, Zhang Y, Tang Y, Butler N, Kim J, Guessous F, Schiff D, Mandell J, Abounader R.

Neoplasia. 2013 Aug;15(8):952-65.

28.

The p53-microRNA-34a axis regulates cellular entry receptors for tumor-associated human herpes viruses.

Kofman AV, Letson C, Dupart E, Bao Y, Newcomb WW, Schiff D, Brown J, Abounader R.

Med Hypotheses. 2013 Jul;81(1):62-7. doi: 10.1016/j.mehy.2013.04.012. Epub 2013 May 2.

29.

Diacylglycerol kinase α is a critical signaling node and novel therapeutic target in glioblastoma and other cancers.

Dominguez CL, Floyd DH, Xiao A, Mullins GR, Kefas BA, Xin W, Yacur MN, Abounader R, Lee JK, Wilson GM, Harris TE, Purow BW.

Cancer Discov. 2013 Jul;3(7):782-97. doi: 10.1158/2159-8290.CD-12-0215. Epub 2013 Apr 4.

30.

Hepatocyte growth factor sensitizes brain tumors to c-MET kinase inhibition.

Zhang Y, Farenholtz KE, Yang Y, Guessous F, Dipierro CG, Calvert VS, Deng J, Schiff D, Xin W, Lee JK, Purow B, Christensen J, Petricoin E, Abounader R.

Clin Cancer Res. 2013 Mar 15;19(6):1433-44. doi: 10.1158/1078-0432.CCR-12-2832. Epub 2013 Feb 5.

31.

Oncogenic effects of miR-10b in glioblastoma stem cells.

Guessous F, Alvarado-Velez M, Marcinkiewicz L, Zhang Y, Kim J, Heister S, Kefas B, Godlewski J, Schiff D, Purow B, Abounader R.

J Neurooncol. 2013 Apr;112(2):153-63. doi: 10.1007/s11060-013-1047-0. Epub 2013 Jan 10.

32.

The role of microRNAs in glioma initiation and progression.

Zhang Y, Dutta A, Abounader R.

Front Biosci (Landmark Ed). 2012 Jan 1;17:700-12. Review.

33.

Cooperation between c-Met and focal adhesion kinase family members in medulloblastoma and implications for therapy.

Guessous F, Yang Y, Johnson E, Marcinkiewicz L, Smith M, Zhang Y, Kofman A, Schiff D, Christensen J, Abounader R.

Mol Cancer Ther. 2012 Feb;11(2):288-97. doi: 10.1158/1535-7163.MCT-11-0490. Epub 2011 Dec 21.

34.

Insight into the role of microRNAs in brain tumors (review).

Catania A, Maira F, Skarmoutsou E, D'Amico F, Abounader R, Mazzarino MC.

Int J Oncol. 2012 Mar;40(3):605-24. doi: 10.3892/ijo.2011.1305. Epub 2011 Dec 15. Review.

PMID:
22179098
35.

When tumor cells make blood vessels: implications for glioblastoma therapy.

Kofman AV, Abounader R.

Future Oncol. 2011 Jul;7(7):841-3. doi: 10.2217/fon.11.58.

36.

The roles of viruses in brain tumor initiation and oncomodulation.

Kofman A, Marcinkiewicz L, Dupart E, Lyshchev A, Martynov B, Ryndin A, Kotelevskaya E, Brown J, Schiff D, Abounader R.

J Neurooncol. 2011 Dec;105(3):451-66. doi: 10.1007/s11060-011-0658-6. Epub 2011 Jul 1. Review.

37.

microRNA-34a is tumor suppressive in brain tumors and glioma stem cells.

Guessous F, Zhang Y, Kofman A, Catania A, Li Y, Schiff D, Purow B, Abounader R.

Cell Cycle. 2010 Mar 15;9(6):1031-6. Epub 2010 Mar 15.

38.

XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC.

Zhang Y, Guessous F, Kofman A, Schiff D, Abounader R.

IDrugs. 2010 Feb;13(2):112-21. Review.

39.

An orally bioavailable c-Met kinase inhibitor potently inhibits brain tumor malignancy and growth.

Guessous F, Zhang Y, diPierro C, Marcinkiewicz L, Sarkaria J, Schiff D, Buchanan S, Abounader R.

Anticancer Agents Med Chem. 2010 Jan;10(1):28-35.

40.

The neuronal microRNA miR-326 acts in a feedback loop with notch and has therapeutic potential against brain tumors.

Kefas B, Comeau L, Floyd DH, Seleverstov O, Godlewski J, Schmittgen T, Jiang J, diPierro CG, Li Y, Chiocca EA, Lee J, Fine H, Abounader R, Lawler S, Purow B.

J Neurosci. 2009 Dec 2;29(48):15161-8. doi: 10.1523/JNEUROSCI.4966-09.2009.

41.

MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes.

Li Y, Guessous F, Zhang Y, Dipierro C, Kefas B, Johnson E, Marcinkiewicz L, Jiang J, Yang Y, Schmittgen TD, Lopes B, Schiff D, Purow B, Abounader R.

Cancer Res. 2009 Oct 1;69(19):7569-76. doi: 10.1158/0008-5472.CAN-09-0529. Epub 2009 Sep 22.

42.

Interactions between PTEN and receptor tyrosine kinase pathways and their implications for glioma therapy.

Abounader R.

Expert Rev Anticancer Ther. 2009 Feb;9(2):235-45. doi: 10.1586/14737140.9.2.235. Review.

43.

Interactions between PTEN and the c-Met pathway in glioblastoma and implications for therapy.

Li Y, Guessous F, DiPierro C, Zhang Y, Mudrick T, Fuller L, Johnson E, Marcinkiewicz L, Engelhardt M, Kefas B, Schiff D, Kim J, Abounader R.

Mol Cancer Ther. 2009 Feb;8(2):376-85. doi: 10.1158/1535-7163.MCT-08-0627. Epub 2009 Feb 3.

44.

Signaling pathways in medulloblastoma.

Guessous F, Li Y, Abounader R.

J Cell Physiol. 2008 Dec;217(3):577-83. doi: 10.1002/jcp.21542. Review.

PMID:
18651559
45.

microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma.

Kefas B, Godlewski J, Comeau L, Li Y, Abounader R, Hawkinson M, Lee J, Fine H, Chiocca EA, Lawler S, Purow B.

Cancer Res. 2008 May 15;68(10):3566-72. doi: 10.1158/0008-5472.CAN-07-6639.

46.

PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations.

Li Y, Guessous F, Kwon S, Kumar M, Ibidapo O, Fuller L, Johnson E, Lal B, Hussaini I, Bao Y, Laterra J, Schiff D, Abounader R.

Cancer Res. 2008 Mar 15;68(6):1723-31. doi: 10.1158/0008-5472.CAN-07-1963.

47.

Transcription-dependent epidermal growth factor receptor activation by hepatocyte growth factor.

Reznik TE, Sang Y, Ma Y, Abounader R, Rosen EM, Xia S, Laterra J.

Mol Cancer Res. 2008 Jan;6(1):139-50. doi: 10.1158/1541-7786.MCR-07-0236.

48.

Functional and molecular interactions between the HGF/c-Met pathway and c-Myc in large-cell medulloblastoma.

Li Y, Guessous F, Johnson EB, Eberhart CG, Li XN, Shu Q, Fan S, Lal B, Laterra J, Schiff D, Abounader R.

Lab Invest. 2008 Feb;88(2):98-111. Epub 2007 Dec 3.

49.

Effect of Akt inhibition on scatter factor-regulated gene expression in DU-145 human prostate cancer cells.

Xu J, Gao M, Fan S, Meng Q, Goldberg ID, Abounader R, Ressom H, Laterra JJ, Rosen EM.

Oncogene. 2007 May 3;26(20):2925-38. Epub 2006 Nov 13.

PMID:
17099727
50.

The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy.

Li Y, Lal B, Kwon S, Fan X, Saldanha U, Reznik TE, Kuchner EB, Eberhart C, Laterra J, Abounader R.

Cancer Res. 2005 Oct 15;65(20):9355-62.

Supplemental Content

Loading ...
Support Center